Starboard Value LP said in its open letter, “There is a better path forward for Bristol-Myers, either as a more profitable standalone company with a more focused, lower-risk strategy, or in a potential sale of the whole Company…While cost cutting and margin improvement is one alternative that we believe is readily available to Bristol-Myers as a standalone entity, the Company’s Board should be open to evaluating all alternatives to create shareholder value, including a sale of the Company. If Bristol-Myers is focused on a potential revenue cliff in its product portfolio, those cliffs can be filled with targeted tuck-in acquisitions, or, alternatively, the Company can become a target for another company to further fill out their product portfolio.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.